Dexmedetomidine and propofol
PreclinicalSmall molecule
Dexmedetomidine and propofol is one of 20 small molecule programs targeting Arrhythmia. It is currently in Preclinical.
2
Indications
5
Total Trials
1
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
20 competitors in Arrhythmia
#DrugCompanyPhaseTrials
1Colcrys
Jazz PharmaceuticalsApproved
Betapace
LLegacy Health System
Approved
Lanoxin
AAdvanz Pharma
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Rythmol Sr
GGlaxo Dba Glaxosmithkline
Approved
Prostigmin
Merck & Co.Preclinical
Robinul
Jazz PharmaceuticalsPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Naropin
FFresenius Kabi USA, LLC
Preclinical
Bridion
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sedation2 trials
Arrhythmia1 trial
Dexmedetomidine1 trial
The Anesthesia Effects of Dexmedetomidine Combined With Desflurane or Propofol in Lobectomy
Recruiting·TThe Second Affiliated Hospital of Chongqing Medical University·N/A·NCT06207344·120 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- AAnesthesia Research Group UA